Biogen

BIIB · NASDAQ

$243.10+$9.62 (+4.12%)TodayMarket closed · Oct 20, 7:52 PM ET

Prev close $233.48

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,500 full-time employees. The firm is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. The company operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. The company also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Employees: 7,500
Headquarters: Cambridge, Massachusetts
Listed: Sep 17, 1991
Sector: Health Care
Industry: Biotechnology
Website: biogen.com

Leadership

Biogen executives
Name	Title	Since	Age
Caroline Dorsa	—	—	66
Christopher Viehbacher	—	2022	65
Robin Kramer	—	—	60
Ginger Gregory	—	—	57
Susan Alexander	—	—	68
Jane Grogan	—	—	58
Rachid Izzar	—	—	50
Adam Keeney	—	—	48
Nicole Murphy	—	—	52
Priya Singhal	—	—	57
Sean Godbout	—	—	50
Maria Freire	—	—	71
William Hawkins	—	—	71
Susan Langer	—	—	34
Jesus Mantas	—	—	56
Lloyd Minor	—	—	67
Sir Menelas Pangalos	—	—	58
Monish Patolawala	—	—	55
Eric Rowinsky	—	—	68
Stephen Sherwin	—	—	76

Revenue by product and region

Fiscal year ended Dec 31, 2025: $9.89B total revenue

By product

Product revenue, net$7.12B72.0%
Revenue from anti-CD20 therapeutic programs$1.86B18.8%
Contract manufacturing, royalty and other revenue$732.90M7.4%
Alzheimer's collaboration revenue$177.70M1.8%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Biogen suppliers and customers
Company	Relationship	Country	Correlation
AC Immune SA ACIU	Supplier	CH	0.93
Catalyst Biosciences CBIO	Supplier and customer	US	0.92
Denali Thrptcs DNLI	Supplier and customer	US	0.90
Sangamo Therapeutics SGMO	Supplier and customer	US	0.90
InnoCare Pharma	Supplier and customer	CN	0.90
Oxford BioDynamics OBD.L	Supplier and customer	GB	0.90
Eisai	Supplier and customer	JP	0.89
bluebird bio, Inc. BLUE	Customer	US	0.89
Quanterix Corporation QTRX	Supplier	US	0.89
908 Devices MASS	Supplier	US	0.88

Similar companies

Companies in the same industry as Biogen

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.